

2 **Enhancing Faecal Egg Count Reduction Tests with ITS2 Nemabiome**

3 Gurnoor Kaur Sydney University 2025

4 **Highlights**

- 5 • Integrated ITS2 Nemabiome with FECRT to enhance assessment of species-level
6 reductions.
- 7 • Hidden BZ and LEV resistance and susceptibility detected across multiple farms.
- 8 • LEV retained a higher efficacy than BZ across most farms and species.
- 9 • Enables the surveillance of emerging resistant species and targeted treatment

10

11 **Abstract**

12 The accelerating development of anthelmintic resistance among gastrointestinal nematodes
13 (GIN) threatens the long-term sustainability of effective parasite control in Merino sheep. The
14 faecal egg count reduction test (FECRT) remains the gold standard for assessing anthelmintic
15 efficacy by calculating the GIN population reduction through the 95% efficacy threshold.
16 However, its accuracy is compromised in mixed-species infections, where morphologically
17 identical eggs are collectively included in the population reduction estimate. Internal
18 Transcribed Spacer 2 (ITS2) Nemabiome represents a deep amplicon sequencing tool that
19 complements FECRT by providing species-specific reductions in mixed-species infections.
20 By integrating these two techniques, we demonstrated how the addition of ITS2 Nemabiome
21 enhances the diagnostic output of FECRT in capturing resistance patterns at the species level
22 rather than at the population level. Three pools of faecal samples were collected across
23 twenty-one Merino sheep farms: a pre-treatment group, a post-Benzimidazole (BZ) group and
24 a post-Levamisole (LEV) group. We conducted faecal egg counts and amplicon sequencing

25 of third-stage larvae to determine species composition and abundance of each treatment.
 26 Integration of ITS2 Nemabiome and FECRT involved scaling the ITS2 proportion reads to
 27 FECRT data to estimate and visualise individual species reductions across the two treatments.
 28 *Haemonchus contortus* was identified as the predominant species whereas LEV achieved a
 29 greater treatment efficacy than BZ. ITS2 Nemabiome revealed cases of hidden susceptibility
 30 and resistance in 63% of farms, providing diagnostic enhancement that would have otherwise
 31 remained undetected by FECRT alone. This work demonstrates the value of integrating ITS2
 32 Nemabiome with FECRT to enhance the detection of emerging GIN species and anthelmintic
 33 resistance within flocks. It also represents an informative diagnostic framework for farmers
 34 that aim to refine their GIN control methods with a targeted and sustainable approach. In line
 35 with this, future research should aim to develop species-specific efficacy thresholds that
 36 address the differences in fecundity and prepatency, aligning with the species-specific
 37 reductions revealed through ITS2 Nemabiome.

38

39 **Graphical Abstract:**

FECRT + ITS2 Nemabiome




Image created by author

40

41 **Keywords**

42 Gastrointestinal nematodes; Anthelmintic resistance, FECRT, ITS2 Nemabiome; Targeted
43 Parasite Control

44

45

46 **1. Introduction:**

47 Control of gastrointestinal nematodes (GIN) in Merino sheep heavily rely on effective
48 anthelmintics to maintain animal health and productivity. However, the accelerating
49 development of anthelmintic resistance, particularly multiple-drug resistance in GIN,
50 threatens the long-term sustainability of these treatments and concurrently the health and
51 welfare of Merino sheep.

52 The faecal egg count reduction test (FECRT) is a traditional, field-based diagnostic test that
53 remains the gold standard for assessing anthelmintic drug efficacy against gastrointestinal
54 nematodes (GIN) (Nielsen, 2021). The test quantifies the percent reduction in GIN egg output
55 following the administration of treatment with reductions greater than 95% indicating a
56 susceptible GIN population (treatment efficacy) and reductions below 95% indicating
57 resistance (treatment inefficacy) (Kaplan et al., 2023).

58 The primary advantages of FECRT lie in its statistical foundation and on-farm applicability,
59 making it a practical and convenient diagnostic tool in livestock systems. The continued
60 recognition of FECRT as the gold standard essentially stems from its validation through the
61 World Association for the Advancement of Veterinary Parasitology (W.A.A.V.P). The
62 W.A.A.V.P guidelines provide protocols, procedures and an explanation of the 95% efficacy
63 threshold, ensuring standardisation across all anthelmintic classes in multiple host and

64 parasite species (Kaplan et al., 2023). Despite this robust foundation, FECRT incurs limited
65 sensitivity and interpretive power when pre-treatment egg counts or sampling sizes are low
66 (Dobson et al., 2012). It also cannot differentiate between GIN species in mixed-species
67 infections as Strongylida produce morphologically indistinguishable eggs (Avramenko et al.,
68 2015). This limits its ability in providing species-specific diagnoses and may obscure the
69 detection of resistant or susceptible species that are concealed in low abundance (Morgan et
70 al., 2022).

71 The Internal Transcribed Spacer 2 (ITS2) Nemabiome approach represents a molecular
72 diagnostic tool that employs DNA metabarcoding to detect and identify GIN communities in
73 pooled third-stage larval (L3) cultures. This technique targets the ITS2 ribosomal DNA
74 region through pan-nematode primers, amplifying a conserved locus that permits interspecific
75 variation across multiple GIN taxa, namely the Strongylida (Avramenko et al., 2015).
76 Through this, ITS2 Nemabiome enables high-throughput sequencing of complex mixed-
77 species infections, offering quantification of individual GIN species by mapping their relative
78 proportions (Redman et al., 2019). This species-specific resolution allows for a more
79 informed assessment of GIN infections by distinguishing species-specific resistance patterns
80 and encouraging the onset of sustainable parasite control through the reduction of
81 unnecessary anthelmintic use (Von Samson-Himmelstjerna et al., 2002). However, species
82 representation bias is a significant limitation. While the ITS2 region is a universal genetic
83 marker for a range of GIN, differences in the number of ITS2 tandem repeats between species
84 may lead to the over-amplification of certain species, manipulating the relative abundance
85 and true species composition within the sample (Avramenko et al., 2015; Von Samson-
86 Himmelstjerna et al., 2002).

87 In this critical backdrop of increasing anthelmintic resistance and shift towards targeted and
88 sustainable parasite control, diagnostic techniques serve as fundamental measures of both the

89 quantitative and qualitative components of GIN infections. However, existing diagnostic
90 methods lack the ability to accurately quantify species composition in mixed-species
91 infections, thereby limiting their capacity to guide informative control strategies that evaluate
92 the anthelmintic performance at the species-level rather than across the entire GIN
93 population. Diagnostic tools must, therefore, evolve to balance these aspects with precision
94 and practicality, which can be achieved through the integration of FECRT with ITS2
95 Nemabiome. By employing FECRT's statistically validated quantitative assessment with
96 ITS2 Nemabiome's species-specific proportional data, this integrated approach has the
97 potential to provide a more comprehensive approach to GIN detection, identification and
98 interpretation to better inform treatment outcomes for farmers.

99 Accordingly, the present study aims to discover whether the application or addition of ITS2
100 Nemabiome will enhance the diagnostic output of FECRT by comparing species-specific
101 reductions to the whole population reduction. Furthermore, it aims to evaluate the value of
102 ITS2 Nemabiome in the context of providing an informed diagnosis that strengthens the
103 reliability of capturing species-specific resistance patterns in GIN infections.

104

105 **2. Materials and Methods:**

106 **2.1 Sample Collection and Treatment**

107 Faecal samples were collected from 21 Merino sheep farms across New South Wales. Each
108 farm was pooled into 3 groups: pre-treatment, post-treatment following benzimidazole
109 administration (BZ) and post-treatment following levamisole administration (LEV) ($n = 63$).
110 Post-treatment samples were collected after 14 days following anthelmintic administration in
111 accordance with W.A.A.V.P guidelines (Kaplan et al., 2023). These faecal samples were

112 transported to the NSW Department of Primary Industries for faecal egg counting and were
113 refrigerated under appropriate conditions.

114

115 **2.2 Faecal Egg Counts and Faecal Egg Count Reduction Test**

116 Faecal egg counts were conducted by the NSW Department of Primary Industries using the
117 mini-FLOTAC method. Faecal egg counts were determined for each treatment (n=63) per
118 farm and tabulated in a spreadsheet. Pre-treatment samples below 150 eggs per gram (EPG)
119 were excluded from the FECRT to ensure the test had sufficient statistical power and
120 sensitivity to detect a valid reduction in GIN population (Kaplan et al., 2023).

121 For the FECRT, we expressed anthelmintic efficacy as a percentage reduction in the egg
122 counts between the post-treatment (BZ and LEV) and the pre-treatment samples, using the
123 W.A.A.V.P guidelines (Kaplan et al., 2023):

124

$$125 \quad \text{Reduction (\%)} = 1 - \left(\frac{(\text{Pre Treatment FEC} - \text{Post Treatment FEC})}{(\text{Pre Treatment FEC})} \right) \times 100$$

126

127 Reductions > 95% were classified as susceptible populations and reductions < 95% were
128 classified as resistant populations. Reductions that were exactly 95% were classified as an
129 inconclusive result as the confidence intervals around this estimate may overlap the resistance
130 threshold and skew the interpretive power of FECRT (Dobson et al., 2012, Kaplan et al.,
131 2023). We tabulated the FECRT values for each farm's treatment in a spreadsheet for further
132 analysis.

133 **2.3 Third-stage Larvae Preparation**

134 Larval cultures of each faecal sample were prepared according to the Australian and New
135 Zealand Standard Diagnostic Procedures (ANZSDP) (Hutchinson, 2009). The faecal cultures
136 were prepared and placed in 400 mL glass jars and incubated at 27 °C for 7 days, permitting
137 the development of third-stage larvae (L3). In order to ensure the L3s grew under optimal
138 conditions, temperature, humidity and sources of contamination and fungal growth were
139 regularly monitored. Following incubation, the L3 were recovered by filling the culture jars
140 with warm water (30 °C) and inverted over a petri dish. The L3 were allowed to stand
141 overnight (approximately 9 hours) to enable larval migration. The water the L3s were placed
142 in were then transferred into 15 mL Falcon tubes and centrifuged at 500 g for 3 minutes to
143 obtain a concentrated larval pellet at the bottom. The samples were stored at 4 °C for
144 downstream DNA isolation.

145 **2.4 DNA Isolation**

146 Before DNA was extracted from the larval samples, the suspensions were examined
147 microscopically to estimate abundance. Only samples with ≥ 2000 larvae were processed to
148 ensure sufficient DNA yield for ITS2 Nemabiome metabarcoding.

149 The larval samples were centrifuged at 1000 g DNA for 2 minutes before the genomic DNA
150 was extracted from the larval pellets using the Monarch Genomic DNA Purification Kit
151 following the manufacturer's instructions for animal tissue specimens (New England Biolabs,
152 Australia). The DNA was eluted from all larval isolates into a final volume of 100 μ L of
153 elution buffer and stored in the freezer at -20°C.

154 **2.5 Serial Dilution**

155 Extracted genomic DNA (100 μ L) was serially diluted in distilled water to obtain a
156 concentration of 1:1000. To reduce the effects of PCR inhibitors and errors, this was
157 conducted through a stepwise dilution series where 45 μ L of distilled water was mixed in

158 each stage (1:10, 1:100, 1:1000). Pipette tips were changed with each stepwise dilution and
159 contact with the microcentrifuge tubes was avoided. The dilutions were stored in the freezer
160 at -20 °C.

161 2.6 Real-time Polymerase Chain Reaction (PCR) for quantification and validation of GIN
162 genomic DNA

163 All real-time PCRs were prepared with 10 µL of SensiFAST™SYBR® No-ROX mix
164 (Meridian Bioscience, Australia), 0.8 µL of NC1 primer (forward), 0.8 µL of NC2 primer
165 (reverse), 6.4 µL of water and 2 µL of the DNA template from the prepared 1:1000 serial
166 dilution samples. Real-time PCR was conducted to quantify and validate the genomic DNA
167 of representative GIN species. The ribosomal DNA of the ITS2 region was amplified using a
168 pair of 'pan-nematode' primers: Strongyl ITS2_F [S0865] (5'- ACG TCT GGT TCA GGG
169 TTG -3') and Strongyl ITS2_R [S0866] (5'- ATG CTT AAG TTC AGC GGG TA-3'),
170 generating amplicons that were approximately 240 base pairs in length (Francis and Šlapeta,
171 2022). PCRs were processed on the CFX Opus 96 Real-Time PCR Detection System where
172 each well of the 96 well plate contained DNA template from a separate diluted sample, one
173 negative control and one blank (water) (BioRad, Australia). The process involved an initial
174 denaturation at 95 °C for 2 minutes, followed by 40 cycles of 95 °C for 5 seconds, 60 °C for
175 15 seconds, 72 °C for 15 seconds and a final melt curve analysis (Francis and Šlapeta, 2022).

176 2.7 ITS2 Nemabiome Metabarcoding

177 ITS2 Nemabiome metabarcoding was conducted to determine the composition of GIN
178 species populations in the pre- and post-treatment samples. Genomic DNA lysates from the
179 L3 cultures were submitted to the Ramaciotti Centre for Genomics (University of New South
180 Wales, Sydney, Australia) for library preparation and Illumina MiSeq sequencing. In
181 summary, a fragment of approximately 311 to 331 base pairs of the ITS2 ribosomal DNA

182 region was amplified using primer pairs containing Illumina sequencing adaptors and random
183 nucleotides to offset the primers and the fluorescence signal during the process of sequencing
184 (Francis and Šlapeta, 2022). Library preparation at the Ramaciotti Centre entailed the
185 attachment of dual index barcodes and sequencing adaptors using the Nextera XT Index Kit
186 V2 (Illumina Inc., USA). The indexed libraries were quantified, normalised, pooled and
187 sequenced on the Illumina MiSeq platform with 2×250 base pairs paired-end reads (Francis
188 and Šlapeta, 2022).

189 **2.8 Bioinformatics and Data Analysis**

190 Raw sequence data included paired forward and reverse reads in the form of FASTQ files.
191 The data was processed and analysed through R using the DADA2 bioinformatic pipeline.
192 The forward and reverse reads underwent primer removal, quality filtering, denoising,
193 merging of the paired-end reads and chimera removal. The remaining amplicon sequence
194 variants (ASVs) were assigned to their respective species through a published
195 trichostrongylid nematode ITS2 rDNA database from nemabiome.ca using the
196 ‘assignTaxonomy’ function (Workentine et al., 2020).

197 The read counts (from DADA2’s ASV table output) for each GIN species per sample were
198 exported to Microsoft Excel and tabulated in a custom spreadsheet. The ITS2 reads of each
199 species were converted into relative proportions within the sample per farm before they were
200 scaled to relative egg counts. The ITS2 proportion reads were scaled to the relative egg
201 counts through the corresponding faecal egg count data from the NSW Department of
202 Primary Industries. From this, samples with pre-treatment egg counts ≤ 150 eggs per gram
203 (EPG) were excluded from analysis in accordance with W.A.A.V.P guidelines (Kaplan et
204 al., 2023).

205 The final calculation involved a reduction map. Pre-treatment counts were set as 100%
206 abundance and the post-treatment values (BZ and LEV) were expressed as percentage
207 reductions relative to the pre-treatment count. Species with reductions < 95% were classified
208 as resistant and species with reductions > 95% were classified as susceptible. Species with
209 reductions as 95% were classified as an inconclusive result.

210 The ITS2 relative proportions, relative egg counts using FECRT data and the reduction map
211 were visualised as clustered column graphs and a connected dot plot for each farm.

212

213 **3. Results**

214 In total, 21 farms were recruited for this study however, after the W.A.A.V.P prerequisite
215 criteria of the 150 EPG pre-treatment count was applied, 16 farms were included for analysis
216 (Kaplan et al., 2023).

217 3.1 Faecal Egg Count Reduction Tests reveal high Benzimidazole Resistance compared to
218 Levamisole Resistance across farms

219 The FECRT was performed using benzimidazole (BZ) and levamisole (LEV) as the
220 anthelmintic treatments for each farm. Across all farms, the mean pre-treatment egg count
221 was 1334 EPG, mean post-treatment (BZ) count was 367 EPG and mean post-treatment
222 (LEV) count was 188 EPG (Fig.1; Appendix A1). For BZ treatment, 14 out of 15 farms
223 (Farm 1 had no BZ data) displayed reductions below 95%, indicating resistance to treatment.
224 Farm 4 showed an increase rather than a decrease following BZ treatment suggesting
225 substantial anthelmintic failure (Fig.1). For LEV, 8 out of 16 farms were resistant to
226 treatment. The mean reduction for BZ treatment across all farms was 72% while the mean
227 reduction for LEV treatment was 79%, demonstrating that LEV was generally more effective
228 at reducing GIN populations than BZ.

229

230 3.2 ITS2 Nemabiome integrated with FECRT demonstrates *Haemonchus contortus* as the
231 Predominant Species and confirms greater Levamisole Efficacy

232 A total of 70 unique ITS-2 Amplicon Sequencing Variants (ASVs) were generated across 62
233 samples. The depth of sequencing varied significantly with an average of 354 reads per
234 sample and a range of 25 reads to 1066 reads. There were 10 GIN species identified and 2
235 identified at the genus level: *Haemonchus contortus*, *Trichostrongylus colubriformis*,
236 *Teladorsagia circumcincta*, *Haemonchus placei*, *Trichostrongylus rugatus*, *Chabertia ovina*,
237 *Cooperia oncophora* *Oesophagostomum venulosum*, *Trichostrongylus axei* and
238 *Trichostrongylus vitrinus* (Table. 1). The read counts per species revealed a dominance of
239 *H.contortus*, followed by *T.circumcincta* and *T.colubriformis*. There were some uncommon
240 species identified including *C.ovina* and *C.oncophora* however, they were present at lower
241 abundances (< 100) and were therefore not retained for further analysis. A threshold for the
242 number of sequencing reads was not applied during this stage. Instead, a threshold was
243 applied post-hoc, whereby samples were excluded if their ITS2 proportional egg counts did
244 not exceed 150 EPG.

245 The ITS2 Nemabiome analysis revealed the presence, proportional abundance and reduction
246 patterns of GIN species for each farm (Fig.2; Appendix A2). *Haemonchus contortus* was the
247 predominant species identified across 14 farms, followed by *Teladorsagia circumcincta* in 7
248 farms and *Trichostrongylus colubriformis* in 3 farms (Fig.2; Appendix A2). In mixed GIN
249 infections (≥ 2 species), farms 3, 5, 7, 9, 10 and 14 displayed significant proportional changes
250 between the post-treatments (Fig.2; Appendix A2).

251 ITS2 proportion reads integrated with the faecal egg counts conveyed how individual species'
252 abundance changed in response to treatment. As the ITS2-derived egg counts were scaled

253 from the proportions of the ITS2 reads, the reductions following BZ and LEV treatment
254 reflected the dominating species per treatment. This trend was further exemplified by the
255 reduction map, which applied a 95% threshold to highlight the GIN species that were
256 resistant or susceptible to treatment.

257 Farms 1, 3 and 4 exhibited GIN species that increased rather than decreased in abundance
258 post-treatment, indicating substantial treatment failure (Fig.2; Appendix A2). Although LEV
259 demonstrated overall greater treatment efficacy than BZ, it was considerably less effective
260 against *T.circumcincta* and *Haemonchus placei* in farms 1 and 3 (Fig.2; Appendix A2).
261 Despite this, the reduction maps portrayed that LEV generally outperformed BZ treatment
262 especially against *H.contortus* which dominated the majority of farms (14/16). For instance,
263 in farms 4, 6, 12, 13, 15 and 19, *H.contortus* was the predominant species, and in five of
264 these six farms, LEV treatment achieved a greater reduction than BZ, demonstrating greater
265 reduction against the species (Fig.2; Appendix A2). Yet, as observed through *T.circumcincta*
266 and *H.placei*, LEV achieved fewer substantial reductions across other GIN species. This trend
267 was evident in farms 1, 5, 7, 9, 10, 14 and 18, where *H.contortus* demonstrated a greater
268 reduction than co-occurring GIN species following LEV treatment (Fig.2; Appendix A2).

269 3.3 Integration of ITS2 Nemabiome and FECRT uncovers Hidden Resistance and 270 Susceptibility

271 To further assess the diagnostic value of combining molecular and traditional methods, ITS2
272 Nemabiome results were compared with corresponding FECRT outcomes (Table 2). The
273 integration revealed several discrepancies between the results, exemplifying the value of
274 species-specific reductions.

275 For BZ treatment, ITS2 Nemabiome integrated with FECRT revealed that farms 5, 11 and 19
276 produced different results to FECRT (Table 2). According to the FECRT results, 14 out of 15

277 (93%) farms were classified as resistant to BZ, however, the detection of susceptible GIN
278 species by ITS2 Nemabiome indicated the presence of hidden susceptibility within mixed-
279 species infections in these farms. It additionally demonstrated that BZ resistance is not as
280 profound as FECRT claims.

281 Regarding LEV treatment, cases of hidden susceptibility and hidden resistance were
282 identified. Although, FECRT found 8 out of 16 farms as resistant to LEV, half of these (50%)
283 farms demonstrated hidden susceptibility through ITS2 Nemabiome (Table 2). Conversely,
284 37.5% of farms classified as susceptible by FECRT (farms 9, 10 and 15) displayed hidden
285 resistance, reflecting the persistence of GIN subpopulations that remained undetected by
286 FECRT. While Farm 14 yielded an “inconclusive” FECRT result and ITS2 Nemabiome
287 yielded a result of “susceptibility”, this farm was not classified as hidden susceptibility due to
288 the uncertainty of the FECRT outcome.

289 Overall, 10 out of 16 farms (63%) incurred additional diagnostic insight from the integration
290 of ITS2 Nemabiome and FECRT.

291

292 **4. Discussion**

293 GIN infections in sheep have long relied on the FECRT for estimating parasite burdens and
294 assessing treatment efficacy. However, PCR-based molecular tools are constantly evolving to
295 easily identify a broader range of GIN species simultaneously, overcoming the limitations of
296 conventional PCR’s species-specific primers (De Seram et al., 2023, Hoglund et al., 2023,
297 Redman et al., 2019). This foundation offers the opportunity for the detection of emerging
298 resistant GIN species, facilitating treatment strategies to be tailored to the farm predominant
299 species and supporting the movement toward targeted parasite management. Consequently,
300 this study demonstrates how integrating the quantitative reduction threshold estimates from

301 FECRT with the qualitative species composition data from ITS2 Nemabiome enhances the
302 overall diagnostic output by linking treatment efficacy to individual species responses, rather
303 than the collective GIN population. This integration reveals nuances such as the dynamic
304 abundance of GIN species relative to treatment response that reflect the onset of anthelmintic
305 resistance (Queiroz et al., 2020).

306 However, in order to successfully delay resistance, an understanding of the flock predominant
307 GIN species and how the respective species individually respond to treatment is necessary.
308 This enables the onset of informed treatment decisions where farmers can selectively use
309 anthelmintics and adopt differing control strategies (e.g. Integrated Parasite Management) to
310 reduce the parasitic burden from dominating species (Queiroz et al., 2020). Findings from the
311 present study demonstrate how integrating ITS2 Nemabiome with FECRT can provide this
312 standard of diagnostic insight. By scaling the ITS2 Nemabiome proportion reads to the faecal
313 egg counts, *H. contortus* was determined as the predominant species across multiple farms.
314 Additionally, applying FECRT's efficacy threshold revealed LEV to achieve greater
315 reductions against GIN species, particularly against *H. contortus*, when compared to BZ. This
316 finding resonated with previous studies that found LEV to be effective against *H. contortus*
317 than other anthelmintics (Andrews, 2000, Ruffell, 2018, Tyrrell and LeJambre, 2010).

318 LEV's mechanisms of action were initially described in Ruffell et al. (2018), who
319 demonstrated that high-level resistance in *H. contortus* is correlated with mutations in the
320 nicotinic acetylcholine receptor subunit genes (target site of LEV) whereas low-level
321 resistance in *H. contortus* is correlated with the overexpression of P-glycoproteins that induce
322 LEV efflux. However, subsequent studies found that these markers were unreliable predictors
323 of LEV resistance and that $\geq 16\%$ of the S168T SNP in the *acr-8* gene is the most valid
324 predictor of high-level LEV resistance (Francis et al., 2024). This exemplifies how the
325 addition of ITS2 Nemabiome can strengthen the interpretation of species-specific resistance

326 patters by demonstrating which species persist after LEV treatment and hence, warrant
327 targeted SNP analysis for a comprehensive assessment of anthelmintic resistance.

328 Although LEV was broadly effective against *H. contortus* and other GIN species, ITS2
329 Nemabiome integrated with FECRT additionally revealed how its diminishing efficacy may
330 require judicious use of the anthelmintic. This was reflected in the post-treatment increase of
331 other GIN species and was further exemplified by the detection of resistant species in FECRT
332 susceptible farms. This implication may reflect anthelmintic preferences, as farmers often
333 favour BZ due to its shorter withdrawal periods (time before the animal product can be sold
334 after the administration of treatment) (Fischer et al., 2025). In this context, the value of
335 integrating species-specific proportion data from ITS2 Nemabiome with FECRT's
336 population-based efficacy threshold, highlights trends in management preferences. It also
337 informs farmers of the importance of treatment rotation that delays anthelmintic resistance
338 and the consequences of prioritising economic productivity over flock health (Fischer et al.,
339 2025). This can encourage farmers to adjust their control strategies by rotating anthelmintic
340 classes, adopting targeted selective treatment (only treating ill animals), quarantining and
341 treating new animals, rotational grazing to disrupt the nematode life cycle and breeding for
342 GIN resistance (Howell et al., 2025).

343 ITS2 Nemabiome complements FECRT by addressing its limitation in species-specific
344 identification and reduction patterns, making it an effective addition for assessing mixed-
345 species infections (Avramenko et al., 2015, Leathwick et al., 2025, Redman et al., 2019).

346 However, an accurate quantification also underpins an enhanced diagnosis. ITS2 Nemabiome
347 may offer greater sensitivity than FECRT due to the reliance on a conserved genetic region
348 rather than morphological GIN eggs, but the accurate quantification of GIN species
349 ultimately remains contingent on the FECRT itself (Avramenko et al., 2015; Hoglund et al.,
350 2023). Since the ITS2 proportion reads are scaled to the faecal egg count values, any

351 inaccuracies in the egg counts will propagate through to the species-specific abundance
352 values, skewing the final classification (resistant, susceptible or inconclusive) and
353 interpretation of the results.

354 However, the factor of accuracy in faecal egg counts is confounded by biological fluctuations
355 in GIN egg shedding, which can facilitate inherently false egg counts. Successful GIN egg
356 production depends on the concurrent presence of both male and female species; therefore, an
357 uneven sex ratio drives a reduced or absent egg population (Rinaldi et al., 2022). Fecundity
358 and the length of the prepatent period also vary across GIN species, with *H. contortus*,
359 displaying higher fecundity and short prepatency (Dobson et al., 2012; Pires et al., 2021),
360 reflecting its predominance across 88% (14/16) of farms. Yet, more fecund and prepatent GIN
361 species will inherently dominate the ITS2 Nemabiome proportion reads and suppress
362 representation of others (Evans et al., 2023). This means that when the proportions are scaled
363 to the faecal egg counts, less fecund and prepatent GIN species may be excluded from
364 analysis as their pre-treatment egg counts will fall below W.A.A.V. P's > 150 EPG threshold
365 (Kaplan et al., 2023). This implies that ITS2 Nemabiome cannot fully rectify FECRT's
366 limitation of inaccurately estimating flock parasite burdens. Nevertheless, given that the
367 quantification of true parasite burdens remain inherently elusive due to the variability in egg
368 shedding, the integration of ITS2 Nemabiome with FECRT represents a robust and practical
369 approach for assessing treatment efficacy in mixed-species infections.

370 While the amalgamation of FECRT's characteristics may aid in validating the interpretive
371 power of GIN infections, W.A.A.V.P's > 150 EPG threshold constrains the inclusion of all
372 GIN species detected by ITS2 Nemabiome. This aspect holds particular significance for
373 targeted parasite control, as it echoes the importance of early detection of emerging species
374 within a flock before they reach diagnostically resistant levels (Le Jambre, 2006). In the
375 present study, multiple GIN species identified by ITS2 Nemabiome were excluded from

376 treatment efficacy analysis as a result of this pre-treatment threshold. Although it could be
377 argued that species with relative abundance $< 0.2\%$ may hold negligible clinical relevance,
378 this circumstance highlights a diagnostic paradox: PCR-based diagnostic tools offer greater
379 sensitivity, capable of detecting all the species within a sample, yet their interpretive power is
380 restricted by thresholds. In this light, the diagnostic value of ITS2 Nemabiome becomes
381 constrained, particularly when only one GIN species such as *H. contortus* is included in
382 treatment efficacy analysis, as observed across 38% (6/16) of farms.

383 Similarly, Fischer et al. (2025) excluded samples with pre-treatment egg count < 200 EPG
384 (for pigs) to reduce false positives however, this approach introduced misclassifications of
385 resistance and inconclusion, increasing uncertainty in both FECRT and ITS2 Nemabiome.
386 Despite this, Leathwick et al. (2025) demonstrated that while the exclusion of low pre-
387 treatment egg counts limits GIN species representation, ITS2 Nemabiome instead enables
388 their inclusion due to its ability to sequence 2000-3000 L3. Its large sampling size permits the
389 formation of tighter confidence intervals around efficacy estimates, suggesting that the
390 inclusion of a pre-treatment threshold may be unnecessary if FECRT were to be coupled with
391 ITS2 Nemabiome (Leathwick et al., 2025). This finding by Leathwick et al. (2025) raises a
392 critical point for the value of integrating FECRT with ITS2 Nemabiome. Currently, the >150
393 EPG threshold ensures the statistical reliability of the FECRT 95% efficacy classification.
394 However, ITS2 Nemabiome's high-throughput sequencing ensures the inclusion of less
395 fecund and prepatent GIN species while maintaining precise efficacy estimates. This implies
396 that, rather than incorporating FECRT's > 150 EPG threshold, the 95% efficacy threshold
397 alone may be sufficient, enhancing the precision of FECRT and enabling ITS2 Nemabiome to
398 capture full species composition and resistance patterns within a flock. For farmers, this
399 would provide more informed diagnoses and treatment outcomes, detecting low abundant or

400 emerging GIN species, that may produce distinct host clinical signs not evident from
401 prevalent species.

402 As next-generation sequencing molecular tools like ITS2 Nemabiome become increasingly
403 employed for enhancing species-specific resolution, current efficacy thresholds may require
404 reassessment for accurate interpretation (Guinda et al., 2025). The 95% efficacy threshold,
405 defined by W.A.A.V.P for FECRT, was produced to assess GIN abundance at the population
406 level, supported by prerequisites such as > 150 EPG pre-treatment egg count, sample size ≥ 5
407 animals and a 14-day period between anthelmintic administration and post-treatment sample
408 collection (Kaplan et al., 2023). In contrast, ITS2 Nemabiome operates through relative
409 species proportions. As the ITS2 proportion reads are scaled to the faecal egg counts, there is
410 an implicit assumption that the relative proportion of sequence reads directly translates to the
411 egg output of each GIN species rather than the entire GIN population. This may distort the
412 interpretive power of the 95% threshold. For instance, an inconclusive result (reduction was
413 95%) was determined for one farm however, ITS2 Nemabiome reported this as a susceptible
414 result. Accordingly, the inconclusion of FECRT's result compromises the validity of ITS2
415 Nemabiome's result and highlights the limitations of applying a fixed population-based
416 threshold to species-specific data (Denwood et al., 2023).

417 Currently, no studies have investigated species-specific efficacy thresholds, and existing
418 studies Queiroz et al. (2020), De Seram et al. (2023), Krücken et al. (2024) have yet to
419 explore the interpretive challenges posed by the integration of ITS2 Nemabiome with
420 FECRT. Future research should aim to establish threshold frameworks that account for
421 biological variability in fecundity and anthelmintic response (Denwood et al., 2023; Krücken
422 et al., 2024). Moreover, an understanding of the genetic markers for resistance through
423 targeted SNP analysis is fundamental to the development of species-specific efficacy
424 thresholds since different anthelmintics incur different mechanisms of action for GIN species

425 (Guinda et al., 2025). This aspect becomes particularly critical when the few GIN species
426 surviving treatment in phenotypically susceptible populations are instead, a small
427 subpopulation of phenotypically resistant GIN species (Guinda et al., 2025). Thus, addressing
428 these gaps will be essential for actioning targeted parasite control, particularly as species-
429 level diagnostic resolution becomes increasingly promoted for sustainable management
430 strategies.

431 Overall, this study demonstrates that ITS2 Nemabiome enhances FECRT's diagnostic value
432 by highlighting species-specific susceptibility and resistance in mixed-species infections.
433 Across 63% (10/16) of studied farms, this integration revealed hidden susceptibility and
434 resistance that would have not been attainable by FECRT, supporting more informed
435 treatment decisions. However, in order to fully utilise the diagnostic aptitude of ITS2
436 Nemabiome, the development of species-specific efficacy thresholds would be required to
437 enhance the accurate detection and interpretation of emerging GIN species. This assessment
438 of emerging GIN species would be valuable for a profound understanding of anthelmintic
439 resistance, particularly in targeted SNP analyses which validates thresholds for phenotypic
440 resistance. Thus, these findings validate the application of ITS2 Nemabiome as a
441 complementary tool to FECRT, enhancing diagnostic interpretation by capturing species-
442 specific dynamics that underpin anthelmintic efficacy.

443

444 **Acknowledgements**

445 We thank Jan Šlapeta for his ongoing guidance, support and valuable feedback throughout
446 this study. We also thank Emily Francis for her assistance in data presentation as well as
447 Janina McKay from the NSW Department of Primary Industries for providing the faecal egg
448 count reduction test data. We are grateful to the participating Merino sheep farms for

449 providing faecal samples. This research was funded by The Australian Wool Education Trust
450 (AWET) Scholarship, which is sincerely acknowledged.

451

452 **References:**

453

454 Andrews, SJ 2000, 'The efficacy of levamisole, and a mixture of oxfendazole and levamisole,
455 against the arrested stages of benzimidazole-resistant *Haemonchus contortus* and
456 *Ostertagia circumcincta* in sheep', *Veterinary Parasitology*, vol. 88,, no. 1-2, pp. 139–
457 146.

458 Avramenko, RW, Redman, EM, Lewis, R, Yazwinski, TA, Wasmuth, JD & Gilleard, JS
459 2015, 'Exploring the Gastrointestinal "Nemabiome": Deep Amplicon Sequencing to
460 Quantify the Species Composition of Parasitic Nematode Communities', *PLOS ONE*,
461 vol. 10, no. 12, pp. 1-18.

462 Coles, GC, Jackson, F, Pomroy, WE, Prichard, RK, von Samson-Himmelstjerna, G, Silvestre,
463 A, Taylor, MA & Vercruyse, J 2006, 'The detection of anthelmintic resistance in
464 nematodes of veterinary importance', *Veterinary Parasitology*, vol. 136, no. 3-4, pp.
465 167–185.

466 De Seram, L, Uehlinger, FD, Camila de Queiroz, Redman, EM, Campbell, JR, Nooyen, D,
467 Morisetti, A, Pollock, CM, Ekanayake, S, Penner, GB & Gilleard, JS 2023,
468 'Integration of ITS-2 rDNA nemabiome metabarcoding with Fecal Egg Count
469 Reduction Testing (FECRT) reveals ivermectin resistance in multiple gastrointestinal
470 nematode species, including hypobiotic *Ostertagia ostertagi*, in western Canadian beef

- 471 cattle', *International Journal for Parasitology: Drugs and Drug Resistance*, vol. 22,
472 pp. 27–35.
- 473 Denwood, MJ, Kaplan, RM, McKendrick, IJ, Thamsborg, SM, Nielsen, MK & Levecke, B
474 2023, 'A statistical framework for calculating prospective sample sizes and
475 classifying efficacy results for faecal egg count reduction tests in ruminants, horses
476 and swine', *Veterinary Parasitology*, vol. 314, pp. 109867.
- 477 Dobson, RJ, Barnes, EH, Birclijin, SD & Gill, JH 1992, 'The survival of *Ostertagia*
478 *circumcincta* and *Trichostrongylus colubriformis* in faecal culture as a source of bias
479 in apportioning egg counts to worm species', *International Journal for Parasitology*,
480 vol. 22, no. 7, pp. 1005–1008.
- 481 Dobson, RJ, Hosking, BC, Jacobson, CL, Cotter, JL, Besier, RB, Stein, PA & Reid, SA 2012,
482 'Preserving new anthelmintics: A simple method for estimating faecal egg count
483 reduction test (FECRT) confidence limits when efficacy and/or nematode aggregation
484 is high', *Veterinary Parasitology*, vol. 186, no. 1-2, pp. 79–92.
- 485 Evans, MJ, Y. Corripio-Miyar, Hayward, A, Kenyon, F, McNeilly, TN & D.H. Nussey 2023,
486 'Antagonism between co-infecting gastrointestinal nematodes: A meta-analysis of
487 experimental infections in Sheep', *Veterinary Parasitology*, vol. 323, pp. 110053–
488 110053.
- 489 Fischer, HR, Jürgen Krücken, Fiedler, S, Thamsborg, SM, Hendrik Nienhoff, Steuber, S,
490 Daher, R & Georg von Samson-Himmelstjerna 2025, 'Faecal egg count reduction test,
491 deep amplicon sequencing of isotype-1 β -tubulin gene and in ovo larval development
492 assay reveal susceptibility to benzimidazoles of porcine nematodes
493 *Oesophagostomum* spp. and *Ascaris suum* in outdoor-reared pigs in Germany',

- 494 *International Journal for Parasitology Drugs and Drug Resistance*, vol. 29, pp.
495 100612–100612.
- 496 Francis, EK, Antonopoulos, A, Mark Edward Westman, McKay-Demeler, J, Laing, R &
497 Šlapeta, J 2024, ‘A mixed amplicon metabarcoding and sequencing approach for
498 surveillance of drug resistance to levamisole and benzimidazole in *Haemonchus* spp.’,
499 *International Journal for Parasitology*, vol. 54, no. 1, pp. 55–64.
- 500 Francis, EK & Šlapeta, J 2022, ‘A new diagnostic approach to fast-track and increase the
501 accessibility of gastrointestinal nematode identification from faeces: FECPAKG2 egg
502 nemabiome metabarcoding’, *International Journal for Parasitology*, vol. 52, no. 6,
503 pp. 331–342
- 504 Godber, OF, Phythian, CJ, Bosco, A, Ianniello, D, Coles, G, Rinaldi, L & Cringoli, G 2015,
505 ‘A comparison of the FECPAK and Mini-FLOTAC faecal egg counting techniques’,
506 *Veterinary Parasitology*, vol. 207, no. 3-4, pp. 342–345.
- 507 Guinda, EFX, Afonso, SMS, Fiedler, S, Morgan, ER, Ramünke, S, Borchert, M, Atanásio, A,
508 Capece, BPS, Krücken, J & von Samson-Himmelstjerna, G 2025, ‘Efficacy of
509 fenbendazole against gastrointestinal nematodes in naturally infected goats in Maputo
510 Province, Mozambique using in vivo, in vitro and molecular assessment’,
511 *International Journal for Parasitology: Drugs and Drug Resistance*, vol. 27, pp.
512 100572.
- 513 Howell, AK, Beechener, ES, Benson, L, Crawford, P, Ewing, DA, Fox, N, Kenyon, F,
514 Kyriazakis, I, Pearce, M, Strain, S & Williams, DJL 2025, ‘Identifying barriers to the
515 sustainable control of gastro-intestinal nematodes in sheep: a social science
516 perspective’, *animal*, vol. 19, no. 5, pp. 101506.

- 517 *INSTRUCTION MANUAL Monarch*® Spin gDNA Extraction Kit NEB #T3010S/L 50/150
518 *preps* 2024, pp. 12–13, viewed 27 March 2025, <[https://www.neb.com/en-au/-](https://www.neb.com/en-au/-/media/nebus/files/manuals/manualt3010.pdf?rev=624b140ff2834dcb9eecffa430909083&hash=D96F02B0EB61B0E0C2853233CA35C42C)
519 [/media/nebus/files/manuals/manualt3010.pdf?rev=624b140ff2834dcb9eecffa4309090](https://www.neb.com/en-au/-/media/nebus/files/manuals/manualt3010.pdf?rev=624b140ff2834dcb9eecffa430909083&hash=D96F02B0EB61B0E0C2853233CA35C42C)
520 [83&hash=D96F02B0EB61B0E0C2853233CA35C42C](https://www.neb.com/en-au/-/media/nebus/files/manuals/manualt3010.pdf?rev=624b140ff2834dcb9eecffa430909083&hash=D96F02B0EB61B0E0C2853233CA35C42C)>.
- 521 Jürgen Krücken, Ehnert, P, Fiedler, S, Horn, F, Helm, CS, Ramünke, S, Bartmann, T, Kahl,
522 A, Neubert, A, Weiher, W, Daher, R, Terhalle, W, Klabunde-Negatsch, A, Steuber, S
523 & Georg von Samson-Himmelstjerna 2024, ‘Faecal egg count reduction tests and
524 nemabiome analysis reveal high frequency of multi-resistant parasites on sheep farms
525 in north-east Germany involving multiple strongyle parasite species’, *International*
526 *Journal for Parasitology Drugs and Drug Resistance*, vol. 25, pp. 100547–100547.
- 527 Kaplan, RM, Denwood, MJ, Nielsen, MK, Thamsborg, SM, Torgerson, PR, Gilleard, JS,
528 Dobson, RJ, Vercruysse, J & Levecke, B 2023, ‘World Association for the
529 Advancement of Veterinary Parasitology (W.A.A.V.P.) guideline for diagnosing
530 anthelmintic resistance using the faecal egg count reduction test in ruminants, horses
531 and swine’, *Veterinary Parasitology*, vol. 318, pp. 109936.
- 532 L.F. Le Jambre 2006, ‘Eradication of targeted species of internal parasites’, *Veterinary*
533 *Parasitology*, vol. 139, no. 4, pp. 360–370.
- 534 Leathwick, D, Green, P, Bouchet, C, Chambers, A, Waghorn, T & Sauermann, C 2025, ‘The
535 faecal egg count reduction test: Will identification of larvae to species improve its
536 utility?’, *International Journal for Parasitology: Drugs and Drug Resistance*, vol. 27,
537 pp. 100589.

- 538 Morgan, ER, Lanusse, C, Rinaldi, L, Charlier, J & Vercruysse, J 2022, 'Confounding factors
539 affecting faecal egg count reduction as a measure of anthelmintic efficacy', *Parasite*,
540 vol. 29, pp. 20.
- 541 Nielsen, MK 2021, 'What makes a good fecal egg count technique?', *Veterinary*
542 *Parasitology*, vol. 296, no. 1, pp. 109509.
- 543 Pires, F, Vinícius, L, Felippelli, G, Buzzulini, C, Maraia, D, Souza, A, Borges, L, Lorena
544 Lopes Ferreira, Santos, Vando Edésio Soares, Arnhold, E, da, J, Fernando & Zanetti,
545 D 2021, 'Investigation of fecal egg counts versus worm burden and helminth fauna in
546 cattle treated or not with macrocyclic lactones in a tropical region', *Veterinary*
547 *Parasitology*, vol. 300, pp. 109618–109618.
- 548 Queiroz, C, Levy, M, Avramenko, R, Redman, E, Kearns, K, Swain, L, Silas, H, Uehlinger, F
549 & Gilleard, JS 2020, 'The use of ITS-2 rDNA nemabiome metabarcoding to enhance
550 anthelmintic resistance diagnosis and surveillance of ovine gastrointestinal
551 nematodes', *International Journal for Parasitology: Drugs and Drug Resistance*, vol.
552 14, pp. 105–117.
- 553 Redman, E, Queiroz, C, Bartley, DJ, Levy, M, Avramenko, RW & Gilleard, JS 2019,
554 'Validation of ITS-2 rDNA nemabiome sequencing for ovine gastrointestinal
555 nematodes and its application to a large scale survey of UK sheep farms', *Veterinary*
556 *Parasitology*, vol. 275, pp. 108933.
- 557 Rinaldi, L, Amadesi, A, Dufourd, E, Bosco, A, Gadanho, M, Lehebel, A, Maurelli, MP,
558 Chauvin, A, Charlier, J, Cringoli, G, Ravinet, N & Chartier, C 2019, 'Rapid
559 assessment of faecal egg count and faecal egg count reduction through composite
560 sampling in cattle', *Parasites & Vectors*, vol. 12, no. 1.

- 561 Ruffell, A, Raza, A, Elliott, TP & Kotze, AC 2018, 'The use of the larval development assay
562 for predicting the in vivo efficacy of levamisole against *Haemonchus contortus* and
563 *Trichostrongylus colubriformis*', *Veterinary Parasitology*, vol. 260, pp. 6–11.
- 564 Sarai, RS, Kopp, S, Knox, M, Coleman, G & Kotze, AC 2015, 'In vitro levamisole selection
565 pressure on larval stages of *Haemonchus contortus* over nine generations gives rise to
566 drug resistance and target site gene expression changes specific to the early larval
567 stages only', *Veterinary Parasitology*, vol. 211, no. 1-2, pp. 45–53.
- 568 Tyrrell, KerriL & LeJambre, LeoF 2010, 'Overcoming macrocyclic lactone resistance in
569 *Haemonchus contortus* with pulse dosing of levamisole', *Veterinary Parasitology*,
570 vol. 168, no. 3-4, pp. 278–283.
- 571 von Samson-Himmelstjerna, G, Harder, A & Schnieder, T 2002, 'Quantitative analysis of
572 ITS2 sequences in trichostrongyle parasites', *International Journal for Parasitology*,
573 vol. 32, no. 12, pp. 1529–1535.
- 574 Workentine, ML, Chen, R, Zhu, S, Gavriliuc, S, Shaw, N, Rijke, J de, Redman, EM,
575 Avramenko, RW, Wit, J, Poissant, J & Gilleard, JS 2020, 'A database for ITS2
576 sequences from nematodes', *BMC Genetics*, vol. 21, no. 1.
- 577
- 578
- 579
- 580

581 **Tables and Figures:**

Species	Number of Reads
<i>H.contortus</i>	1020122
<i>T.colubriformis</i>	76289
<i>T.circumcinta</i>	388161
<i>H.placei</i>	2615
<i>T.rugatus</i>	1660
<i>C.ovina</i>	19
<i>C.oncophora</i>	58
<i>O.venulosum</i>	5050
<i>T.axei</i>	10160
<i>T.vitrinus</i>	2195

Table 1. Distribution of ITS2 amplicon sequencing reads

The read counts reflect the total number of sequences assigned to each species following quality filtering and taxonomic classification (n=62).

582

583

FARM ID	FECRT Result (BZ)	ITS2 Nemabiome + FECRT Result (BZ)	Hidden Resistance?	Hidden Susceptibility?	FECRT Result (LEV)	ITS2 Nemabiome + FECRT Result (LEV)	Hidden Resistance?	Hidden Susceptibility?
FARM 1	n.d.	n.d.	n.d.	n.d.	Resistant	Mixed	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
FARM 3	Resistant	Resistant	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Resistant	Mixed	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
FARM 4	Resistant	Resistant	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Resistant	Resistant	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
FARM 5	Resistant	Mixed	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Resistant	Mixed	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
FARM 6	Resistant	Resistant	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Susceptible	Susceptible	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
FARM 7	Resistant	Resistant	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Resistant	Mixed	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
FARM 8	Resistant	Resistant	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Resistant	Resistant	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
FARM 9	Resistant	Resistant	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Susceptible	Mixed	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
FARM 10	Resistant	Resistant	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Susceptible	Mixed	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
FARM 11	Resistant	Mixed	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Susceptible	Mixed	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
FARM 12	Resistant	Resistant	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Susceptible	Susceptible	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
FARM 13	Resistant	Resistant	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Susceptible	Susceptible	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
FARM 14	Resistant	Resistant	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Inconclusive	Susceptible	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
FARM 15	Susceptible	Susceptible	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Susceptible	Mixed	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
FARM 18	Resistant	Resistant	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Resistant	Resistant	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
FARM 19	Resistant	Susceptible	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Resistant	Mixed	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>

Table 2. Comparison of Faecal Egg Count Reduction Test (FECRT) and ITS2 Nemabiome integrated with FECRT results for benzimidazole (BZ) and levamisole (LEV) across different farms.

A "Mixed" result signifies the presence of both resistant and susceptible species in a farm. "Hidden Resistance" indicates instances where ITS2 Nemabiome detected resistant species not apparent in FECRT, and "Hidden Susceptibility" indicates instances where ITS2 Nemabiome detected susceptible species not detected by FECRT. "n.d." denotes data not available.




Figure 1. Faecal egg counts (EPG) of Pre-treatment, Post-treatment (BZ) and Post-Treatment (LEV).

Faecal egg counts were measured for six representative farms before (pre-treatment) and 14 days (post-treatment) after the administration of BZ and LEV.






Figure 2. Integration of ITS2 Nemabiome and FECRT data across six farms.

Each panel of the farm displays the ITS2 proportion reads (left), ITS2 proportion reads scaled to the faecal egg counts (middle) and a species reduction map (right). The species reduction map represents the proportion of the pre-treatment population remaining post-treatment (pre-treatment assumed as 100%). The purple dashed line represents the efficacy threshold (5%), separating resistant (red zone; < 95%) and susceptible (green zone; > 95%) species.




Appendix Figure A1. Faecal egg counts (EPG) of Pre-treatment, Post-treatment (BZ) and Post-Treatment (LEV) across the remaining ten farms.

587

588

589




590

591

592

593

594




595

596

597

598

599




600

601

602

603

604





605


606

607

608

609





Appendix Figure A2. Integration of ITS2 Nemabiome and FECRT data across the remaining ten farms.

Each panel of the farm displays the ITS2 proportion reads (left), ITS2 proportion reads scaled to the faecal egg counts (middle) and a species reduction map (right). The species reduction map represents the proportion of the pre-treatment population remaining post-treatment (pre-treatment assumed as 100%). The purple dashed line represents the efficacy threshold (5%), separating resistant (red zone; < 95%) and susceptible (green zone; > 95%) species.